

Alberta Drug Benefit List (ADBL) interim update now available online

Please be advised that the **December 1, 2022** updates to the *Alberta Drug Benefit List (ADBL)* have been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the December 1, 2022 updates for complete listings of products available by special authorization, step therapy/special authorization, restricted benefit/special authorization, added products, products with a price change and discontinued products.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application and, as such, contains the most up-to-date information.

Temporary benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Jamp Spironolactone 100 mg Tablet (DIN 02518848) manufactured by Jamp Pharma Corporation, Mint-Spironolactone 100 mg Tablet (DIN 02488159) manufactured by Mint Pharmaceuticals Inc., and Teva-Spironolactone 100 mg Tablet (DIN 00613223) manufactured by Teva Canada Limited, **Aldactone 100 mg Tablet (DIN 00285455)** manufactured by Pfizer Canada ULC, will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was previously added to the Critical Supply Product List on **October 10, 2022**.

As of **November 21, 2022**, and until further notice, all claims for Aldactone 100 mg Tablet (DIN 00285455) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)*. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

continued next page

continued from previous page

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Auro Pharma Inc., Jamp Pharma Corporation and Pharmascience Inc. that the shortage for Auro-Losartan 25 mg Tablet (DIN 02403323), Jamp-Losartan 25 mg Tablet (DIN 02398834) and pms-Losartan 25 mg Tablet (DIN 02309750), respectively, has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **December 15, 2022**. The following grouping was removed from the Critical Supply Product List on **November 15, 2022**.

LOSARTAN POTASSIUM

25 MG TABLET

00002379058	APO-LOSARTAN	APX	\$ 0.1616
00002403323	AURO-LOSARTAN	AUR	\$ 0.1616
00002398834	JAMP-LOSARTAN	JPC	\$ 0.1616
00002388790	LOSARTAN	SIV	\$ 0.1616
00002388863	LOSARTAN	SNS	\$ 0.1616
00002405733	MINT-LOSARTAN	MPI	\$ 0.1616
00002309750	PMS-LOSARTAN	PMS	\$ 0.1616
00002313332	SANDOZ LOSARTAN	SDZ	\$ 0.1616
00002424967	SEPTA-LOSARTAN	SEP	\$ 0.1616
00002380838	TEVA-LOSARTAN	TEV	\$ 0.1616
00002182815	COZAAR	ORC	\$1.4504

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
 403-294-4041 (Calgary and area)
 1-800-361-9632 (toll free)
 FAX 780-498-8406 (Edmonton and area)
 FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

